Cite
HARVARD Citation
Barley, K. et al. (n.d.). Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2. American journal of hematology. 95 (2), pp. E51-E54. [Online].